about
Effect of hypoxia on the expression of αB-crystallin in head and neck squamous cell carcinomaAdrenal Steroid Metabolites Accumulating in Congenital Adrenal Hyperplasia Lead to Transactivation of the Glucocorticoid ReceptorADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinomaRat steroid 5 alpha-reductase kinetic characteristics: extreme pH-dependency of the type II isozyme in prostate and epididymis homogenatesMolecular profiling of platinum resistant ovarian cancer.Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS.Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors.Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response.HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor modelActivation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.Downregulation of serine protease HTRA1 is associated with poor survival in breast cancerDistinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma.Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study.Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response.Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKTTargeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer.Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients.Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcomePredictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models.Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors.Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients.ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligandsThe topography of mutational processes in breast cancer genomes.A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.Identifying estrogen receptor target genes.Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.Crosstalk and DC-SCRIPT: expanding nuclear receptor modulation.Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.
P50
Q21261248-101B335C-92DB-4E67-BB7B-87921111367CQ28265511-24AF3D04-9920-4315-9CFE-81ACD4B4082AQ28271466-2DC52D92-F23B-44CC-8CC6-612D289E703DQ28572433-22F9ED8C-3216-4F3D-88CD-DC195501E4FBQ33227163-5DE8E828-8D3A-4695-9C68-51BD56020DF4Q33234978-0F7D8DD4-90CD-4C2A-A20C-64CC3D7453E0Q33360774-9D7FBC36-3876-48D2-B338-5B5FC0586567Q33395871-2F37CAD3-3D1F-4ABA-AEF4-C6F9ABA70F03Q33739577-2D655B39-219E-4740-B015-F9AA401D2192Q33850657-9A1B10F2-F521-4909-BE61-12163DE91E32Q34036107-7C2DA6AF-B950-4284-A19F-0DE71194493CQ34046731-82AA6AEA-FBE0-42D5-9082-38D10F67F117Q34205104-6EDDFD83-7015-4D2D-8D6D-C68195D96D8DQ34436771-9BFAD295-8FBE-47DD-800A-2983B3EA72F8Q34613612-B3D6225D-F2B9-4A88-AB83-727CA9BFE5D8Q34666305-C8658252-0860-4C5C-BF0D-659F1EF6EEE9Q34754660-BA8DFAAF-06DA-495F-A003-0A8641618DF9Q35078927-8982AA42-A522-4601-A0AD-DAAE7F4FEB93Q35234637-B7AD3578-1FD7-4AD9-8055-4410F96F0698Q35608727-4FB752AC-E4AF-42CD-91E0-C0E02296948CQ35664110-042938BB-C6D5-4281-A6FB-2CBA6AFFB50BQ35749170-F14A1BE1-33F9-4EF8-81E5-42E612C5A7B4Q35836156-9EDEA499-4476-420F-8BAE-C84399264BFEQ35950845-5C66F381-8804-49AE-9363-48C62CBA75D4Q36147166-B33A40CA-B105-4305-AE2F-BA019E04BF43Q36384058-FDB770F9-70DC-4DCE-B936-2D3F8CA74B3AQ36670928-46B63F94-3E6E-46FC-BFD5-5CAAE2489B6EQ36770297-6ABEC548-D8E8-4A40-87CB-4EDDFB20E15CQ36772047-B58C0E20-E0B5-465F-BD4D-79BA84FE270CQ37060946-D116AB3E-1686-46DA-A450-92C72F40F147Q37202473-1027C59B-DFAB-4EE1-A5F5-9F7ECC83B99DQ37207706-F1C5B68B-8901-49BE-9815-0EE4E5C83205Q37211361-1212FE69-70A6-482B-838E-8D2BB0D8EACEQ37231848-7029E93E-FABC-4970-B64A-3225E2723E8AQ37315121-66A87BE6-B6A5-4D63-9196-0E2ED2351A52Q37321593-72DCB079-928B-4D7C-AEC8-B76EE30AD9B3Q37453798-04BEF822-8E1F-4AD9-B380-4D14CD3558F1Q37634494-D39EB875-CCFA-402D-8760-6C25DE9428E9Q37755603-F71E04C5-FC84-4EA6-8227-619CD86CE060Q38052537-B887253E-E3C4-4C84-AF48-D27067570BA8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul N Span
@ast
Paul N Span
@en
Paul N Span
@es
Paul N Span
@nl
type
label
Paul N Span
@ast
Paul N Span
@en
Paul N Span
@es
Paul N Span
@nl
prefLabel
Paul N Span
@ast
Paul N Span
@en
Paul N Span
@es
Paul N Span
@nl
P106
P31
P496
0000-0002-1930-6638